Intelgenx Technologies (FRA:0IL) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Intelgenx Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Intelgenx Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Intelgenx Technologies ROCE % Historical Data

The historical data trend for Intelgenx Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies ROCE % Chart

Intelgenx Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-97.13

-122.11

-91.29

-110.56

-241.49

Intelgenx Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-350.83	-	-3,264.71	-152.53	-

Intelgenx Technologies ROCE % Calculation

Intelgenx Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.613	/	( ( (8.675 - 2.241)	+	(7.595 - 7.724) )	/ 2 )
	=	-7.613	/	( (6.434	+	-0.129)	/ 2 )
	=	-7.613	/	3.1525
	=	-241.49 %

Intelgenx Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-11.904	/	( ( (7.595 - 7.724)	+	(6.024 - 15.195) )	/ 2 )
	=	-11.904	/	( ( -0.129	+	-9.171 )	/ 2 )
	=	-11.904	/	-4.65
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Intelgenx Technologies (FRA:0IL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Intelgenx Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelgenx Technologies (FRA:0IL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (FRA:0IL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IGXT:USA 0IL:Germany IGX:Canada

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.

Intelgenx Technologies (FRA:0IL) Headlines

No Headlines